BioCryst Pharma (BCRX) Reports In-Line Q3 EPS ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to BioCryst Pharma (BCRX) Reports In-Line Q3 EPS ; Offers Guidance
November 4, 2024 2:20 PM EST
Piper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BCRX shares after this mornings Q324 Orladeyo beat and narrowed FY24 Orladeyo revenue... More
November 4, 2024 2:06 PM EST
(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "BCRX reported $116.3mn in 3Q Orladeyo sales, slightly ahead of our $113.7mn and consensus $112.6mn. Mgmt highlights strong patient demand, noting US start forms were up 14.2% over the past 12 months and the paid drug rate improved to 74.8% (2Q: 74.4%). Additionally, 67 new US prescribers were added in 3Q, which is the highest add in the past eight quarters. The company narrowed FY24 Orladeyo sales guidance to... More
